Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BiomX Inc.
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
Public Company Edition: Valuations have fallen enough in 2022 to lead some companies to wind down operations, but a recent uptick opened a window for a few offerings. Chinook raised $105m in a follow-on offering, while Flagship led a $79.2m registered direct offering for Evelo.
Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
- Drug Discovery Tools
- Other Names / Subsidiaries
- BiomX Ltd.
- Chardan Healthcare Acquisition Corp.
- RondinX Ltd.